Medpace Holdings, Inc. (MEDP)
POSITIVE基本面
69
价格
$611.49
市值
$17.31B
第一部分 · 这家公司值多少
概览
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
资产负债表与流动性
营收
$2.78B
最近12个月（截至2026/6/30）
净利润
$492M
最近12个月（截至2026/6/30）
自由现金流
$682M
股东权益合计
$459M
负债合计
$1.52B
流动比率
0.73
利息覆盖率
-
债务/EBITDA
0.24
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$847.98
当前价格
$611.49
安全边际
+27.9%
公允价值区间
$551.19 - $1144.77
估算方法
估值指标
市盈率（P/E）
36.39
ROE
98.3%
市净率（P/B）
39.89
P/FCF
24.49
毛利率
-
ROIC
74.1%
盈利能力雷达图
Value Creation (Economic Moat)
ROIC
74.1%
WACC
10.9%
ROIC − WACC
+63.2 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
基本面分析标准
通过（17）
- EPS shows upward trend
- Price CAGR 32.92%
- ROIC 74.1%
- P/FCF 24.49
- Debt/Equity ratio
- Operating Margin 21.0%
- Positive Free Cash Flow
- CapEx intensity
- Debt/EBITDA
- Return on Tangible Assets
- ROE 110.1%
- Revenue Growth 5Y 22.3%
- Earnings Surprise avg 7.5%
- PEG Ratio 1.05
- Earnings Quality (OCF/NI) 1.53
- Share Dilution -7.8%
- Piotroski F-Score 6/9
未通过（7）
- P/B Ratio 39.89
- Current Ratio
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Analyst Consensus 35% Buy
- Net Margin Trend 17.7% vs 18.7%
不可用（3）
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
Piotroski F-评分
信号混杂：部分领域需关注
盈利质量
高质量：盈利有现金流支撑
股权稀释
正在回购股份，对股东友好
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Dr. August James Troendle M.D. | CEO, President & Chairman | 69 |
| Mr. Kevin M. Brady | CFO & Treasurer | 50 |
| Mr. Stephen P. Ewald J.D. | Chief Compliance Officer, General Counsel & Corporate Secretary | 56 |
| Mr. Brad W. Hansman | Executive Vice President of Operations | 42 |
| Ms. Lauren Morris | Associate Director of Investors Relations | - |
| Mr. Todd Meyers | Vice President of Business Development & Marketing | - |
| Mr. Weimin Gai MS | Senior Vice President of Biometrics | - |
| Mr. John T. Wynne MBA | Chief Business Officer | - |
| Ms. Reinilde Heyrman M.D. | Chief Medical Officer of Medical Department | 64 |
| Ms. Gina Leisring M.P.H. | Senior Vice President of Clinical Monitoring | - |
审计风险
6
董事会风险
8
薪酬风险
4
股东权利风险
5
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。
Latest News
Recent headlines for MEDP, sourced from Markets Gazette.